Mitochondrial pathology in Parkinson's disease and implications for therapeutic intervention

被引:0
|
作者
Swerdlow, RH [1 ]
Parker, WD [1 ]
机构
[1] Univ Virginia, Hlth Sci Ctr, Dept Neurol, Charlottesville, VA 22908 USA
关键词
mitochondria; Parkinson's disease; mitochondrial DNA; therapy;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although the ultimate origin and role of mitochondrial pathology in Parkinson's disease (PD) remains controversial, accumulating data suggest that mitochondrial dysfunction is genetic and plays an important role in neurodegeneration. PD mitochondria display abnormal electron transport chain activity, increased reactive oxygen species generation, and abnormal calcium handling. These abnormalities arise, at least in part, from information encoded by mitochondrial DNA. These processes are implicated in current models of neuronal death and validate ongoing efforts to develop mitochondrial-level pharmacologic interventions for the treatment of this disease. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:44 / 50
页数:7
相关论文
共 50 条
  • [21] Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease
    Yang, Yunseon
    Song, Jae-Jin
    Choi, Yu Ree
    Kim, Seong-Hoon
    Seok, Min-Jong
    Wulansari, Noviana
    Darsono, Wahyu Handoko Wibowo
    Kwon, Oh-Chan
    Chang, Mi-Yoon
    Park, Sang Myun
    Lee, Sang-Hun
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (29)
  • [22] Parkinson's disease and neuroinflammation - Cellular pathology, mechanisms and therapeutic options
    Toenges, Lars
    Metzdorf, Judith
    Zella, Samis
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2018, 86 : S10 - S20
  • [23] SIAH proteins regulate the degradation and intra-mitochondrial aggregation of PINK1: Implications for mitochondrial pathology in Parkinson's disease
    Abd Elghani, Fatimah
    Safory, Hazem
    Hamza, Haya
    Savyon, Mor
    Farhoud, Malik
    Toren-Hershoviz, Michal
    Vitic, Zagorka
    Ebanks, Kirsten
    Shani, Vered
    Bisharat, Sleman
    Shaulov, Lihi
    Brodski, Claude
    Song, Zhiyin
    Bandopadhyay, Rina
    Engelender, Simone
    AGING CELL, 2022, 21 (12)
  • [24] Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention
    Lim, Ji Woong
    Lee, Jiyoun
    Pae, Ae Nim
    BMB REPORTS, 2020, 53 (01) : 47 - 55
  • [25] Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
    Martin T. Henrich
    Wolfgang H. Oertel
    D. James Surmeier
    Fanni F. Geibl
    Molecular Neurodegeneration, 18
  • [26] Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential
    Henrich, Martin T.
    Oertel, Wolfgang H.
    Surmeier, D. James
    Geibl, Fanni F.
    MOLECULAR NEURODEGENERATION, 2023, 18 (01)
  • [27] Erythropoietin and Parkinson's disease: Suggested mechanisms, and therapeutic implications
    Genc, Kursad
    MEDICAL HYPOTHESES, 2008, 70 (01) : 211 - 212
  • [28] Gene therapeutic strategies for neuroprotection: Implications for Parkinson's disease
    Bowers, WJ
    Howard, DF
    Federoff, HJ
    EXPERIMENTAL NEUROLOGY, 1997, 144 (01) : 58 - 68
  • [29] The clinical heterogeneity of Parkinson's disease and its therapeutic implications
    Greenland, Julia C.
    Williams-Gray, Caroline H.
    Barker, Roger A.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 328 - 338
  • [30] Parkinson's disease following hypothyroidism: clinical and therapeutic implications
    Kacem, I.
    Gargouri, A.
    Ben Djebara, M.
    Zekri, H.
    Hizem, Y.
    Gouider, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S291 - S291